我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

抽象的

Harnessing the Power of Targeted RNA Therapies for Cancer Treatment and Immunomodulation

Zhuoran Yu

Targeted RNA therapies have emerged as a promising frontier in the quest for more effective and personalized approaches to cancer treatment and immunomodulation. This article explores the potential of RNA-based therapies in both contexts, highlighting their precision and versatility. Small interfering RNA (siRNA) and microRNA (miRNA) therapies can selectively silence or regulate genes associated with cancer, while messenger RNA (mRNA) vaccines hold promise for training the immune system to combat malignancies. In the realm of immunomodulation, RNA-based strategies like CAR-T cell therapy and immune checkpoint inhibitors are revolutionizing cancer care. Challenges in delivery and off-target effects persist, but ongoing research and innovation are paving the way for a brighter future where RNA therapies become integral components of comprehensive cancer treatment.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证。